These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29589533)

  • 1. Liver and Statins: A Critical Appraisal of the Evidence.
    Licata A; Giammanco A; Minissale MG; Pagano S; Petta S; Averna M
    Curr Med Chem; 2018; 25(42):5835-5846. PubMed ID: 29589533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of pharmacogenetic variation on the effects of statins.
    Maggo SD; Kennedy MA; Clark DW
    Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
    Canestaro WJ; Austin MA; Thummel KE
    Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic marker of statin-induced rhabdomyolysis].
    Chiba K; Morimoto K
    Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinician's guide to statin drug-drug interactions.
    Kellick KA; Bottorff M; Toth PP; The National Lipid Association's Safety Task Force
    J Clin Lipidol; 2014; 8(3 Suppl):S30-46. PubMed ID: 24793440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic basis of drug-induced liver injury: present and future.
    Urban TJ; Daly AK; Aithal GP
    Semin Liver Dis; 2014 May; 34(2):123-33. PubMed ID: 24879978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of genetic factors in statins side-effects.
    Scarpini F; Cappellone R; Auteri A; Puccetti L
    Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):35-43. PubMed ID: 22524173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iatrogenic myopathies.
    Mastaglia FL
    Curr Opin Neurol; 2010 Oct; 23(5):445-9. PubMed ID: 20581681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
    Nicoletti P; Aithal GP; Bjornsson ES; Andrade RJ; Sawle A; Arrese M; Barnhart HX; Bondon-Guitton E; Hayashi PH; Bessone F; Carvajal A; Cascorbi I; Cirulli ET; Chalasani N; Conforti A; Coulthard SA; Daly MJ; Day CP; Dillon JF; Fontana RJ; Grove JI; Hallberg P; Hernández N; Ibáñez L; Kullak-Ublick GA; Laitinen T; Larrey D; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Powell EE; Qin S; Serrano J; Stephens C; Stolz A; Wadelius M; Watkins PB; Floratos A; Shen Y; Nelson MR; Urban TJ; Daly AK;
    Gastroenterology; 2017 Apr; 152(5):1078-1089. PubMed ID: 28043905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Induced Liver Injury from Statins.
    Meurer L; Cohen SM
    Clin Liver Dis; 2020 Feb; 24(1):107-119. PubMed ID: 31753243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical response to statins: mechanism(s) of variable activity and adverse effects.
    Sirtori CR; Mombelli G; Triolo M; Laaksonen R
    Ann Med; 2012 Aug; 44(5):419-32. PubMed ID: 21623698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis.
    Zechner J; Britza SM; Farrington R; Byard RW; Musgrave IF
    Life Sci; 2022 Feb; 291():119975. PubMed ID: 34560084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-cardiovascular effects associated with statins.
    Desai CS; Martin SS; Blumenthal RS
    BMJ; 2014 Jul; 349():g3743. PubMed ID: 25035309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and adverse drug reactions: the case of statins.
    Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
    Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
    Norata GD; Tibolla G; Catapano AL
    Pharmacol Res; 2014 Oct; 88():107-13. PubMed ID: 24835295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
    Hua WJ; Hua WX; Fang HJ
    Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.